LIEGE, BELGIUM / ACCESSWIRE / September 13, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of enrollment and initial dosing in the Phase 1 portion of its adaptive Phase 1/2 clinical trial, IMCY-MS-001. The Phase 1 open-label, dose escalation part of the study is assessing the safety of three doses of Imotope™ IMCY-0141 in patients with relapsing-remitting multiple sclerosis (RRMS).
LIEGE, BELGIUM / ACCESSWIRE / March 1, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced completion of patient enrollment in its Phase 2 IMPACT ( IM CY-0098 P roof of AC tion in T ype 1 Diabetes) trial of its lead product candidate IMCY-0098, a proinsulin-derived Imotope™ engineered to halt the progression and prevent early-onset Type 1 diabetes (T1D).
IMCY-MS-001 study aims to determine safety profile, optimal dosing regimen and initial efficacySecond Imotopeâ„¢ from proprietary technology platform moves into clinic; interim results are expected in...
LIÈGE, Belgium, March 14, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the...
LIÈGE, Belgium, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the Company’s lead candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to treat and prevent T1D. The Company also reported that the study reached the midpoint of recruitment and both the U.S. Food and Drug Administration (FDA) and Australian Therapeutics Goods Administration (TGA) approved the Company’s Investigational New Drug (IND) application to initiate the study in these two countries.
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, announced the appointment of Gene Mack, MBA, as Chief Financial Officer.